Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
A HCP called to inquire about the administration spacing of GARDASIL 9 for a patient who received their first dose at age 15 in 10/2019 but may need the second and third doses now at age 20.; No additional AE nor PQC; Information has been received from Business Partner/CRO on 11-Apr-2025. This spontaneous report was received from a/an Pharmacist and refers to a(n) 20-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9). On an unknown date, the patient experienced A HCP called to inquire about the administration spacing of GARDASIL 9 for a patient who received their first dose at age 15 in 10/2019 but may need the second and third doses now at age 20.. On an unknown date, the patient experienced No additional AE nor PQC. At the reporting time, the outcome of A HCP called to inquire about the administration spacing of GARDASIL 9 for a patient who received their first dose at age 15 in 10/2019 but may need the second and third doses now at age 20. and No additional AE nor PQC was unknown.